We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Chevron (CVX - Free Report) , Pfizer (PFE - Free Report) and Boeing (BA - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Chevron has handily outperformed the Zacks Integrated Oil Industry over the past year (up +5.4% vs. +0.3%), as well as larger rival ExxonMobil which saw its stock go down -8.7% over the same time period. Chevron's gains reflect the momentum generated by better-than-expected earnings in 3 of the last 4 quarters on the back of rebounding commodity prices, lower expenses and improved U.S. refining environment.
Moreover, Chevron's focus on the prolific Permian basin should allay investor fears about production growth trajectory over the next few years. However, with oil testing the psychologically-critical $50 threshold again, the near-to-medium term revenue outlook for Chevron – one of the most oil-weighted majors – remains cloudy.
Chevron is still outspending its cash flow, making it dependent on asset sales. Hence, the Zacks analyst thinks investors should wait for a better entry point before buying shares in America's second largest oil company.
Shares of Pfizer have underperformed the peer group as well as the broader market over the past year (the stock is down -4.3% over the last year vs. a +5.5% increase for the Zacks Large-Cap Pharma industry and the +16.8% gain for the S&P 500 index) on continued drug pricing uncertainty that have refused to go away even after the election. These headwinds notwithstanding, the Zacks analyst is pointing out that Pfizer is strengthening its product portfolio as well as pipeline through acquisitions and licensing deals.
Also, cost-savings and share buybacks should help Pfizer achieve its earnings guidance. New products like Ibrance and contribution from acquisitions are expected to drive revenues. While the Hospira acquisition has significantly expanded Pfizer's sterile injectable and biosimilar capabilities, the Medivation deal has strengthened its cancer franchise by adding Xtandi to its portfolio.
Boeing’s shares have surged +49.5% over the past one-year, outperforming the Zacks Aerospace & Defense sector, which gained +26.8% during the same time period. The Zacks analyst stresses that rising demand for its commercial airplanes on the back of steady improvement in passenger and freight traffic is the major factor behind the surge in Boeing shares.
These developments reflect the company’s latest expansion on the international front, apart from its strong presence in the domestic aviation market. The improving outlook for defense spending under the Trump administration is another long-term positive in the Boeing story.
However, challenges including uncertain fate of high-cost programs, risks related to key project executions, order cancellations as well as stiff competition might have a negative impact on the company. Also deferred production cost for Boeing’s 787 Dreamliner remains a major cause of concern for the company.
Other noteworthy reports we are featuring today include Comcast CMSA, 3M (MMM - Free Report) and Citigroup (C - Free Report) .
3 Stocks to Ride a 588% Revenue Explosion At Zacks, we're mostly focused on short-term profit cycles, but the hottest of all technology mega-trends is starting to take hold...
By last year, it was already generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. See Zacks' Top 3 Stocks to Ride This Space >>
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trendsand Earnings Previewreports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Top Stock Reports for Chevron, Pfizer & Boeing
Monday June 19 2017
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Chevron (CVX - Free Report) , Pfizer (PFE - Free Report) and Boeing (BA - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Chevron has handily outperformed the Zacks Integrated Oil Industry over the past year (up +5.4% vs. +0.3%), as well as larger rival ExxonMobil which saw its stock go down -8.7% over the same time period. Chevron's gains reflect the momentum generated by better-than-expected earnings in 3 of the last 4 quarters on the back of rebounding commodity prices, lower expenses and improved U.S. refining environment.
Moreover, Chevron's focus on the prolific Permian basin should allay investor fears about production growth trajectory over the next few years. However, with oil testing the psychologically-critical $50 threshold again, the near-to-medium term revenue outlook for Chevron – one of the most oil-weighted majors – remains cloudy.
Chevron is still outspending its cash flow, making it dependent on asset sales. Hence, the Zacks analyst thinks investors should wait for a better entry point before buying shares in America's second largest oil company.
(You can read the full research report on Chevron here >>>).
Shares of Pfizer have underperformed the peer group as well as the broader market over the past year (the stock is down -4.3% over the last year vs. a +5.5% increase for the Zacks Large-Cap Pharma industry and the +16.8% gain for the S&P 500 index) on continued drug pricing uncertainty that have refused to go away even after the election. These headwinds notwithstanding, the Zacks analyst is pointing out that Pfizer is strengthening its product portfolio as well as pipeline through acquisitions and licensing deals.
Also, cost-savings and share buybacks should help Pfizer achieve its earnings guidance. New products like Ibrance and contribution from acquisitions are expected to drive revenues. While the Hospira acquisition has significantly expanded Pfizer's sterile injectable and biosimilar capabilities, the Medivation deal has strengthened its cancer franchise by adding Xtandi to its portfolio.
(You can read the full research report on Pfizer here >>>).
Boeing’s shares have surged +49.5% over the past one-year, outperforming the Zacks Aerospace & Defense sector, which gained +26.8% during the same time period. The Zacks analyst stresses that rising demand for its commercial airplanes on the back of steady improvement in passenger and freight traffic is the major factor behind the surge in Boeing shares.
These developments reflect the company’s latest expansion on the international front, apart from its strong presence in the domestic aviation market. The improving outlook for defense spending under the Trump administration is another long-term positive in the Boeing story.
However, challenges including uncertain fate of high-cost programs, risks related to key project executions, order cancellations as well as stiff competition might have a negative impact on the company. Also deferred production cost for Boeing’s 787 Dreamliner remains a major cause of concern for the company.
(You can read the full research report on Boeing here >>>).
Other noteworthy reports we are featuring today include Comcast CMSA, 3M (MMM - Free Report) and Citigroup (C - Free Report) .
3 Stocks to Ride a 588% Revenue Explosion
At Zacks, we're mostly focused on short-term profit cycles, but the hottest of all technology mega-trends is starting to take hold...
By last year, it was already generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. See Zacks' Top 3 Stocks to Ride This Space >>
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>